Vitamin D Replacement for Adolescent Females with PCOS

This study is looking at how vitamin D affects adolescent females (ages 13-21) who have Polycystic Ovarian Syndrome (PCOS) and low vitamin D levels. PCOS is a common hormone problem that can cause irregular periods, acne, and excess hair growth. Participants will receive either Vitamin D 4000IU daily or a placebo (an inactive pill) for 6 months. Researchers want to see if Vitamin D 4000IU daily can improve irregular periods and increase vitamin D levels. To join, you must be a female between 13 and 21, have PCOS, and have a vitamin D level between 6-29 ng/mL. The study aims to enroll 60 participants.

Study design
This is a double-blind, placebo-controlled, randomized study, meaning neither you nor the study team will know if you are receiving Vitamin D 4000IU daily or the placebo. It plans to include 60 participants.
What's involved
You would be followed for 6 months, with repeat blood tests at the start, 3 months, and 6 months. These tests include vitamin D, hormone levels, and blood sugar checks.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for 6 months after starting the treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04355572

Evaluation of the Clinical and Psychological Impact of Vitamin D Replacement in Adolescent Females at Risk for Polycystic Ovarian Syndrome (PCOS)

Recruiting
NAAges 13–21InterventionalTreatment
Yale University
~60 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:Vitamin D 4000IU dailyPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in oligomenorrhea
Measured over 6 months
+1 more outcome measured
Polycystic Ovarian Syndrome in Adolescent Females
Vitamin D Deficiency

NCT04355572

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Yale New Haven Children's Hospital

    New Haven, Connecticutstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Alla Vash-Margita, MD · PRINCIPAL_INVESTIGATOR · Yale University

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Other causes for hyperandrogenism,
Chronic renal diseases,
Acquired or inherited calcium and vitamin D metabolic disorders.
  • Change in oligomenorrhea6 months

    The change in oligomenorrhea, i.e restoration of monthly menses or improvement in the menstrual pattern during 6 months while enrolled in the trial based on self report

  • Changes Vitamin D (25-hydroxyvitamin D) levelat enrollment, at 3 months after randomization and 6 months after randomization

    25-hydroxyvitamin D level will be measured by liquid chromatography-mass spectrometry (LC-MS/MS) or immunoassay